Zymeworks (ZYME) to Release Quarterly Earnings on Wednesday

Zymeworks (NASDAQ:ZYME) will likely be posting its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Zymeworks to post earnings of ($0.35) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $23.29 on Monday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -27.73 and a beta of 1.23. The stock’s 50-day moving average is $23.98 and its 200-day moving average is $20.81. Zymeworks has a one year low of $9.03 and a one year high of $28.49.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ZYME shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, January 21st. Citigroup assumed coverage on shares of Zymeworks in a research report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Citizens Jmp set a $32.00 price target on shares of Zymeworks in a research report on Wednesday, December 3rd. Wall Street Zen downgraded Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company raised Zymeworks from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $25.00 to $33.00 in a research report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.90.

Insiders Place Their Bets

In other Zymeworks news, CEO Kenneth Galbraith sold 54,343 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, for a total value of $1,364,009.30. Following the transaction, the chief executive officer directly owned 158,286 shares in the company, valued at $3,972,978.60. The trade was a 25.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul Andrew Moore sold 20,110 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $25.10, for a total transaction of $504,761.00. Following the completion of the transaction, the insider owned 31,212 shares in the company, valued at approximately $783,421.20. This trade represents a 39.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 187,933 shares of company stock worth $4,673,716. Company insiders own 33.51% of the company’s stock.

Institutional Investors Weigh In On Zymeworks

Several institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Zymeworks in the fourth quarter worth about $55,000. Quarry LP acquired a new position in Zymeworks during the 3rd quarter worth approximately $50,000. Tower Research Capital LLC TRC lifted its stake in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after purchasing an additional 1,131 shares during the last quarter. Brooklyn Investment Group acquired a new stake in Zymeworks in the fourth quarter valued at approximately $214,000. Finally, VARCOV Co. acquired a new stake in Zymeworks in the fourth quarter valued at approximately $259,000. 92.89% of the stock is currently owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.